Recent advances in atopic dermatitis

Leung, 2019, The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype, Sci Transl Med, 11, 10.1126/scitranslmed.aav2685 Goleva, 2019, Epithelial barrier repair and prevention of allergy, J Clin Invest, 129, 1463, 10.1172/JCI124608 Kim, 2019, Pathophysiology of atopic dermatitis: clinical implications, Allergy Asthma Proc, 40, 84, 10.2500/aap.2019.40.4202 Leung, 2019, The microbiome and allergic diseases: a struggle between good and bad microbes, Ann Allergy Asthma Immunol, 122, 231, 10.1016/j.anai.2019.01.003 Lee, 2019, A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis, J Am Acad Dermatol, 80, 1526, 10.1016/j.jaad.2018.05.1241 Chiesa Fuxench, 2019, Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population, J Invest Dermatol, 139, 583, 10.1016/j.jid.2018.08.028 Patel, 2019, Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis, J Am Acad Dermatol, 80, 402, 10.1016/j.jaad.2018.08.063 Ascott, 2019, Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies, J Allergy Clin Immunol, 143, 1821, 10.1016/j.jaci.2018.11.030 Kim, 2019, Racial/ethnic differences in incidence and persistence of childhood atopic dermatitis, J Invest Dermatol, 139, 827, 10.1016/j.jid.2018.10.029 Levin, 2020, Environmental factors associated with allergy in urban and rural children from the South African Food Allergy (SAFFA) cohort, J Allergy Clin Immunol, 145, 415, 10.1016/j.jaci.2019.07.048 Wan, 2019, Mental health impairment among children with atopic dermatitis: a U.S. population-based cross-sectional study of the 2013-2017 National Health Interview Survey, J Am Acad Dermatol Hoffman, 2019, Association of atopic dermatitis with increased risk of anaphylaxis to egg and milk, Ann Allergy Asthma Immunol, 123, 620, 10.1016/j.anai.2019.09.008 McKenzie, 2019, The prevalence and persistence of atopic dermatitis in urban United States children, Ann Allergy Asthma Immunol, 123, 173, 10.1016/j.anai.2019.05.014 Abuabara, 2018, The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies, Allergy, 73, 696, 10.1111/all.13320 Calov, 2020, The association between season of birth and atopic dermatitis in the Northern hemisphere: a systematic review and meta-analysis, J Allergy Clin Immunol Pract, 8, 674, 10.1016/j.jaip.2019.10.007 Rutter, 2019, Are environmental factors for atopic eczema in ISAAC Phase Three due to reverse causation?, J Invest Dermatol, 139, 1023, 10.1016/j.jid.2018.08.035 Huls, 2018, Atopic dermatitis: interaction between genetic variants of GSTP1, TNF, TLR2, and TLR4 and air pollution in early life, Pediatr Allergy Immunol, 29, 596, 10.1111/pai.12903 Huls, 2019, Nonatopic eczema in elderly women: effect of air pollution and genes, J Allergy Clin Immunol, 143, 378, 10.1016/j.jaci.2018.09.031 Stefanovic, 2020, The exposome in atopic dermatitis, Allergy, 75, 63, 10.1111/all.13946 Kim, 2018, Significance of skin barrier dysfunction in atopic dermatitis, Allergy Asthma Immunol Res, 10, 207, 10.4168/aair.2018.10.3.207 Drislane, 2020, The role of filaggrin in atopic dermatitis and allergic disease, Ann Allergy Asthma Immunol, 124, 36, 10.1016/j.anai.2019.10.008 Ding, 2020, Epidermal mammalian target of rapamycin complex 2 controls lipid synthesis and filaggrin processing in epidermal barrier formation, J Allergy Clin Immunol, 145, 283, 10.1016/j.jaci.2019.07.033 Elias, 2019, EMSY expression affects multiple components of the skin barrier with relevance to atopic dermatitis, J Allergy Clin Immunol, 144, 470, 10.1016/j.jaci.2019.05.024 Suga, 2019, Keratinocyte proline-rich protein deficiency in atopic dermatitis leads to barrier disruption, J Invest Dermatol, 139, 1867, 10.1016/j.jid.2019.02.030 Boiten, 2019, The cornified envelope-bound ceramide fraction is altered in patients with atopic dermatitis, J Invest Dermatol Berdyshev, 2018, Lipid abnormalities in atopic skin are driven by type 2 cytokines, JCI Insight, 3, 10.1172/jci.insight.98006 Baurecht, 2018, Epidermal lipid compostion, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration, J Allergy Clin Immunol, 141, 1668, 10.1016/j.jaci.2018.01.019 Kamijo, 2019, Increased IL-26 expression promotes T helper type 17- and T helper type 2-associated cytokine production by keratinocytes in atopic dermatitis, J Invest Dermatol Yoshihara, 2019, IL-10-producing regulatory B cells are decreased in patients with atopic dermatitis, J Invest Dermatol, 139, 475, 10.1016/j.jid.2018.08.016 Brauweiler, 2019, Staphylococcus aureus lipoteichoic acid damages the skin barrier through an IL-1-mediated pathway, J Invest Dermatol, 139, 1753, 10.1016/j.jid.2019.02.006 Brauweiler, 2019, Staphylococcus aureus lipoteichoic acid initiates a TSLP-basophil-IL4 axis in the skin, J Invest Dermatol, 10.1016/j.jid.2019.02.006 Ryffel, 2019, ILC2s and basophils team up to orchestrate IL-33-induced atopic dermatitis, J Invest Dermatol, 139, 2077, 10.1016/j.jid.2019.06.118 Liang, 2019, Thymic stromal lymphopoietin epigenetically upregulates Fc receptor gamma subunit-related receptors on antigen-presenting cells and induces TH2/TH17 polarization through dectin-2, J Allergy Clin Immunol, 144, 1025, 10.1016/j.jaci.2019.06.011 Paller, 2019, The microbiome in patients with atopic dermatitis, J Allergy Clin Immunol, 143, 26, 10.1016/j.jaci.2018.11.015 Woo, 2020, The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis, J Am Acad Dermatol, 82, 222, 10.1016/j.jaad.2019.08.078 Callewaert, 2020, IL-4Ralpha blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis, J Invest Dermatol, 140, 191, 10.1016/j.jid.2019.05.024 Yu, 2019, A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor, J Allergy Clin Immunol, 143, 2108, 10.1016/j.jaci.2018.11.036 Smits, 2020, Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHR-dependent induction of antimicrobial peptides, J Invest Dermatol, 140, 415, 10.1016/j.jid.2019.06.142 Simpson, 2020, Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial, JAMA Dermatol, 156, 44, 10.1001/jamadermatol.2019.3336 Faiz, 2019, Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort, J Am Acad Dermatol, 81, 143, 10.1016/j.jaad.2019.02.053 Kim, 2020, Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream, J Allergy Clin Immunol, 145, 572, 10.1016/j.jaci.2019.08.042 Igelman, 2020, Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review, J Am Acad Dermatol, 82, 407, 10.1016/j.jaad.2019.10.010 Silverberg, 2020, Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus, J Allergy Clin Immunol, 145, 173, 10.1016/j.jaci.2019.08.013 Nakagawa, 2019, Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis, J Allergy Clin Immunol, 144, 1575, 10.1016/j.jaci.2019.08.004 Guttman-Yassky, 2019, GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis, J Allergy Clin Immunol, 144, 482, 10.1016/j.jaci.2018.11.053 Czarnowicki, 2019, Atopic dermatitis endotypes and implications for targeted therapeutics, J Allergy Clin Immunol, 143, 1, 10.1016/j.jaci.2018.10.032 Peppers, 2019, A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis, J Am Acad Dermatol, 80, 89, 10.1016/j.jaad.2018.06.047 Simpson, 2019, Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial, J Am Acad Dermatol, 80, 1013, 10.1016/j.jaad.2018.11.059 Simpson, 2019, A phase 2 randomized trial of apremilast in patients with atopic dermatitis, J Invest Dermatol, 139, 1063, 10.1016/j.jid.2018.10.043 Brunner, 2019, Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab, J Allergy Clin Immunol, 143, 142, 10.1016/j.jaci.2018.07.028 Wollenberg, 2019, Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb, J Allergy Clin Immunol, 143, 135, 10.1016/j.jaci.2018.05.029 Guttman-Yassky, 2019, Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study, J Am Acad Dermatol, 80, 913, 10.1016/j.jaad.2018.01.018 Guttman-Yassky, 2018, Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial, J Am Acad Dermatol, 78, 872, 10.1016/j.jaad.2018.01.016